|
T stage
|
FEC arm [cases (%)]
|
P value
|
PE arm [cases (%)]
|
P value
|
|---|
|
Baseline
|
After NACT
|
Baseline
|
After NACT
|
|---|
|
Total
|
151
|
151
|
<0.001
|
142
|
142
|
<0.001
|
|
0
|
0 (0.00)
|
5 (3.31)
| |
0 (0.00)
|
12 (8.45)
| |
|
1
|
0 (0.00)
|
46 (30.46)
| |
0 (0.00)
|
62 (43.66)
| |
|
2
|
106 (70.20)
|
77 (50.99)
| |
86 (60.65)
|
55 (38.73)
| |
|
3
|
43 (28.48)
|
9 (6.62)
| |
52 (36.62)
|
5 (3.52)
| |
|
4
|
2 (1.32)
|
5 (2.65)
| |
4 (2.82)
|
2 (1.41)
| |
|
Missing
|
0 (0.00)
|
9a (5.96)
| |
0 (0.00)
|
6b (4.23)
| |
-
FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen
-
aOf the 9 patients, 2 had migrated to other cities and were not restaged, 5 declined further treatment and were not restaged, and 2 were lost to follow-up
-
bOf the 6 patients, 5 declined further treatment and were not restaged, and 1 was lost to follow-up
